|
Colonic Neoplasms
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Cdx1 inhibits human colon cancer cell proliferation by reducing beta-catenin/T-cell factor transcriptional activity.
|
15215241 |
2004 |
|
Colonic Neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
CDX2 heterozygous-null mice develop colonic neoplasms, which have suggested that CDX2 is a tumor suppressor.
|
16314840 |
2006 |
|
Colonic Neoplasms
|
0.360 |
AlteredExpression
|
group |
LHGDN |
The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells.
|
17599044 |
2008 |
|
Colonic Neoplasms
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Differential regulation of CDX1 and CDX2 gene expression by deficiency in methyl group donors.
|
18187048 |
2008 |
|
Colonic Neoplasms
|
0.360 |
AlteredExpression
|
group |
LHGDN |
Silencing of CDX2 expression in colon cancer via a dominant repression pathway.
|
12947088 |
2003 |
|
Colonic Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
The CDX2 transcription factor is expressed in intestinal epithelium and is markedly down-regulated in colon tumours.
|
11161380 |
2001 |
|
Colonic Neoplasms
|
0.360 |
Biomarker
|
group |
CTD_human |
The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms.
|
29439001 |
2018 |
|
Precancerous Conditions
|
0.300 |
Biomarker
|
group |
CTD_human |
The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms.
|
29439001 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas.
|
28029907 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, only A33 was compared with CDX2 for a tissue microarray (TMA)-based study of primary adenocarcinomas with different origins: CRC (n = 55), liver deposits of metastatic CRC (n = 60), breast (n = 101), lung (n = 40), oesophagogastric tract (n = 134), ovary (n = 67), pancreas (n = 77), and prostate (n = 56).
|
28226180 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Histopathological and immunohistochemical examination revealed a well-differentiated adenocarcinoma (strongly positive staining for cytokeratin 20 and CDX2), pT3N0 stage IIA.
|
29556659 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CDX2 is a marker of colon cancer, with strong staining in up to 90% of colonic adenocarcinomas.
|
16314840 |
2006 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The maximal induction of CDX2 expression was seen in SEG-1 adenocarcinoma cells.
|
17458588 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, an inverse correlation between CDX2 expression and tumor grade, tumor stage and lymph node metastasis in colorectal adenocarcinomas has been reported.
|
19795349 |
2009 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Sensitivity for CDX2 in metastasis from colorectal adenocarcinomas was 93%; while in SATB2 it was 79%.
|
29924451 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CDX2 seems to be a marker for cellular phenotype better than an indicator of the origin of adenocarcinomas.
|
15894926 |
2005 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
LHGDN |
CDX2 seems to be a marker for cellular phenotype better than an indicator of the origin of adenocarcinomas.
|
15894926 |
2005 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no CDX2 protein expression in normal squamous esophagus, but moderate to strong protein expression was seen in all Barrett's tissues and in a majority of the dysplasia and adenocarcinoma cells.
|
16291394 |
2005 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Caudal homeobox gene-2 (CDX-2) is a specific and robust marker for colonic adenocarcinomas and can also be used to identify differentiation of mature intracranial teratoma into colonic-type adenocarcinoma.
|
31520753 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Metastatic colorectal adenocarcinomas were positive for CK20 (100%), CDX-2 (100%), and PDX-1 (33%), whereas were negative for CA-125 and CK7.
|
18665037 |
2008 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the adenocarcinomas were positive for MUC6 (4/5), PAX8 (3/5), CK7 (5/5), CK20 (1/5), CDX2 (5/5), CA19.9 (5/5), CEA (4/5), CA125 (5/5), and hepatocyte nuclear factor 1β (5/5). p16, estrogen receptor, and Napsin A were negative in all cases tested, whereas p53 exhibited mutation-type staining in 3/5 cases.
|
29664741 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
LHGDN |
All breast, nonmucinous ovarian, and most endometrial and pancreatic adenocarcinomas showed no immunoreactivity for CDX2.
|
15722794 |
2005 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the adenocarcinomas were positive for CK7 (4/4), CEA (4/4), MUC6 (3/3), PAX8 (3/4), CK20 (2/4), CDX2 (2/4), and estrogen receptor (1/4).
|
31567280 |
2020 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CDX2, a transcription factor of the caudal homeobox family, plays a key role in intestinal development and differentiation, and it is widely used as a marker to detect adenocarcinomas of intestinal and colonic origin.CDX2 has been rarely reported in PTC.
|
23488912 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined the association between COX-2 and DCAMKL1 expression in gastric carcinomas in clinical samples (early gastric well-differentiated adenocarcinoma) and Cdx2-transgenic mice; and the DCAMKL1-transgenic mouse stomach using immunohistochemistry and quantitative real-time polymerase chain reaction.
|
25228975 |
2014 |